No attachments available.
A--Drug Manufacturing and Formulation Program (DMFP)
Contact and place of performance
PLUGGE, RIEKA N
Menlo Park, CA
USA
Four (4) Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts with a maximum ordering value of $49,999,999.00 and an ordering period from May 4, 2026 through May 3, 2036, were awarded on May 4, 2026. Concurrently, the first task orders were issued to each awardee with an effective date of May 4, 2026 through July 3, 2026, in the firm-fixed price amount totaling $5,000.00.
The National Institutes of Health, National Institute on Drug Abuse (NIDA) awarded four Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for the Drug Manufacturing and Formulation Program (DMFP) on May 4, 2026. These contracts, identified under solicitation number 75N95024R00077, have a combined maximum ordering value of $49,999,999.00 and an ordering period extending through May 3, 2036. The primary place of performance is Menlo Park, California, with Rieka N. Plugge serving as the point of contact.
The acquisition is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC AN11 for Health R&D Services; Health Care Services; Basic Research. There was no set-aside designated for this award. Concurrent with the IDIQ awards, the agency issued initial firm-fixed-price task orders to each of the four awardees totaling $5,000.00. These task orders are effective from May 4, 2026, through July 3, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.